<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220167</url>
  </required_header>
  <id_info>
    <org_study_id>OND/CR/051/08/09</org_study_id>
    <nct_id>NCT01220167</nct_id>
  </id_info>
  <brief_title>Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water</brief_title>
  <official_title>Open-label, Randomized, Three-way Crossover Bioavailability Study Comparing Ondansetron Orally Dissolving Filmstrip (ODFS) With and Without Water to Zofran Orally Dissolving Tablets (ODT) Without Water in Healthy Adult Study Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquestive Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquestive Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study conducted in healthy male and female adult participants compared the&#xD;
      bioavailability and relative safety and tolerance of a single dose of ondansetron 8 mg Orally&#xD;
      Dissolving Filmstrip (ODFS) administered under fasting conditions with and without water with&#xD;
      that of a single dose of Zofran Orally Dissolving Tablets (ODT®) containing ondansetron 8 mg&#xD;
      administered under fasting conditions without water.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, single oral dose,randomized sequence, three-way crossover study to&#xD;
      compare the bioavailability, safety and tolerability of ondansetron 8 mg Orally Dissolving&#xD;
      Filmstrip (ODFS) administered without (Test Treatment A) and with water (Test Treatment B)&#xD;
      with that of Zofran Orally Dissolving Tablets (ODT®) containing ondansetron 8 mg administered&#xD;
      without water (Reference Treatment C) in healthy adult participants. The 3 treatment&#xD;
      sequences were: ABC, BCA, and CAB, in which, all treatments were administered after an&#xD;
      overnight fasting of at least 10 hours in each period.&#xD;
&#xD;
      Participants reported to the study site between 07:30 am to 04:30 pm on 22 Aug 2008, 25 Aug&#xD;
      2008, and 28 Aug 2008 for Period 1, Period 2, &amp; Period 3, respectively. Participants were&#xD;
      served dinner between 8:00 pm to 8:30 pm, to ensure a minimum of 10 hours of fasting prior to&#xD;
      administration of a single dose of either the test or reference product. Participants were&#xD;
      dosed as per the randomization schedule with a 3-day wash out period between each&#xD;
      administration.&#xD;
&#xD;
      A total of 18 blood samples (4 mL each) were collected from each subject in each period for&#xD;
      pharmacokinetic analyses. Safety assessments including monitoring of adverse events, periodic&#xD;
      physical examination, and vital signs monitoring. Urine Drug Screening was done at the time&#xD;
      of check-in of all the study periods to identify participants with any substance abuse. Urine&#xD;
      pregnancy screen (for female subjects only) was scheduled at the time of screening and at&#xD;
      admission for Period 1, Period 2, Period 3. A clinical assessment, which included general and&#xD;
      systemic examination, was done at the pre-study screening and post study physical&#xD;
      examination. Clinical laboratory hematology and chemistry tests were performed at screening&#xD;
      (pre-study) and at the study follow-up visit (post-study).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open label, balanced, randomized three period, three treatment, three sequence, three-way crossover bioavailability study .</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Maximum Plasma Concentration (Time to reach maximum concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (e.g., &quot;0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose&quot;)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
    <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8 mg ODFS without water</intervention_name>
    <description>Single dose of Ondansetron 8 mg (ODFS) administered without water</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <other_name>Test Treatment (A)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8 mg ODFS with water</intervention_name>
    <description>Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <other_name>Test Treatment (B)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran ODT (ondansetron 8 mg) without water</intervention_name>
    <description>Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <other_name>Reference Treatment (C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The criteria for inclusion in the study were:&#xD;
&#xD;
          -  Study volunteer should provide written informed consent.&#xD;
&#xD;
          -  Study volunteer must be a healthy adult within 18-45 years of age (inclusive).&#xD;
&#xD;
          -  Study volunteer should have a Body mass index of ≥ 18.5 kg/m2 and ≤ 25 kg/m2, with&#xD;
             body weight not less than 50 kg.&#xD;
&#xD;
          -  Study volunteer should have a systolic blood pressure with upper limit of less than&#xD;
             140 mmHg and lower limit of more than or equal to 90 mm Hg.&#xD;
&#xD;
          -  Study volunteer must be of normal health as determined by medical history and physical&#xD;
             examination performed within 15 days prior to the dosing of period 1.&#xD;
&#xD;
          -  Study volunteer should have a normal ECG, chest X-ray and vital signs.&#xD;
&#xD;
          -  If study volunteer is a female and is of child bearing potential she must be&#xD;
             practicing an acceptable method of birth control for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The criteria for exclusion from the study were:&#xD;
&#xD;
          -  Study volunteer incapable of understanding the informed consent.&#xD;
&#xD;
          -  Study volunteer with a history of hypersensitivity or idiosyncratic reaction to study&#xD;
             drug or any other related drug.&#xD;
&#xD;
          -  Study volunteer having any evidence of impairment of renal, hepatic, cardiac, lung or&#xD;
             gastrointestinal function.&#xD;
&#xD;
          -  Study volunteers with a history of tuberculosis, epilepsy, asthma (during past 5&#xD;
             years), diabetes, psychosis or glaucoma&#xD;
&#xD;
          -  Study volunteer who smokes regularly more than ten cigarettes daily.&#xD;
&#xD;
          -  Study volunteer who has taken over the counter or prescribed medications.&#xD;
&#xD;
          -  Study volunteer with a history of any psychiatric illness, which may impair the&#xD;
             ability to provide written, informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudershan Vishwanath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Ltd.</affiliation>
  </overall_official>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>July 25, 2011</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Fifty-five healthy adult volunteers were screened for study eligibility between 18 Aug 2008 and 21 Aug 2008 at VIMTA VHS Research Centre in Adyar, Chennai - 600 113, India.</recruitment_details>
      <pre_assignment_details>Eighteen of 55 subjects were randomized. Of those not randomized, 29 did not meet eligibility criteria and 6 declined to participate. The 18 eligible participants reported to the study site on 22 Aug 2008, 25 Aug 2008 and 28 Aug 2008 for Period 1, Period 2, &amp; Period 3, respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence ABC</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT containing ondansetron 8 mg without water).</description>
        </group>
        <group group_id="P2">
          <title>Sequence BCA</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water).</description>
        </group>
        <group group_id="P3">
          <title>Sequence CAB</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Urine positive for substance abuse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence ABC</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT containing ondansetron 8 mg without water).</description>
        </group>
        <group group_id="B2">
          <title>Sequence BCA</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water).</description>
        </group>
        <group group_id="B3">
          <title>Sequence CAB</title>
          <description>Each subject received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="7.57"/>
                    <measurement group_id="B2" value="31.1" spread="8.27"/>
                    <measurement group_id="B3" value="28.8" spread="5.98"/>
                    <measurement group_id="B4" value="28.2" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="0.07"/>
                    <measurement group_id="B2" value="22.8" spread="0.78"/>
                    <measurement group_id="B3" value="22.9" spread="1.95"/>
                    <measurement group_id="B4" value="23.7" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum Plasma Concentration (Time to reach maximum concentration)</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <population>18 subjects were enrolled. One subject did not complete.</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS With or Without Water and Zofran ODT</title>
            <description>Single dose of Ondansetron ODFS 8 mg film administered with and then without water and Zofran 8 mg administered without water</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum Plasma Concentration (Time to reach maximum concentration)</description>
          <population>18 subjects were enrolled. One subject did not complete.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ODFS without water</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.866" spread="13.3089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODFS with water</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.843" spread="15.9103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zofran ODT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.382" spread="12.3572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCt</title>
        <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (e.g., &quot;0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose&quot;)</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <population>18 healthy subjects were enrolled. Only 17 subjects completed the study. 0 to 96 hours post-dose</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS With and Without Water and Zofran ODT</title>
            <description>Single dose of Ondansetron ODFS 8 mg film with and again without water and Zofran 8 mg without water</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt</title>
          <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (e.g., &quot;0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose&quot;)</description>
          <population>18 healthy subjects were enrolled. Only 17 subjects completed the study. 0 to 96 hours post-dose</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ODFS without water</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.687" spread="106.5203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODFS with water</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.069" spread="99.5911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zofran ODT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.457" spread="105.3048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf</title>
        <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
        <time_frame>0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose</time_frame>
        <population>18 subject were enrolled. Only 17 completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS With and Without Water and Zofran ODT</title>
            <description>Single dose of Ondansetron ODFS 8 mg film with water and without water and Zofran 8 mg without water</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf</title>
          <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
          <population>18 subject were enrolled. Only 17 completed the study.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ODFS without water</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.349" spread="119.7910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODFS with water</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.394" spread="112.7499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zofran ODT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.497" spread="121.8256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time of the first dose until 30 days following the last dose (overall approximately 1.5 months for each subject). No adverse events were reported during the study and follow-up period. Clinical laboratory hematology and chemistry tests were performed at screening (pre-study) and at the study follow-up visit (post-study). Thus, abnormal laboratory analytes reported as adverse events could not be attributed to any of the 3 study treatments.</time_frame>
      <desc>All adverse events (AE) were recorded from the time of the first dose until the last follow-up visit scheduled 48 hours following the last dose of study intervention. Serious adverse events (SAEs) were reported from the time of the first dose until 30 days following the last dose.&#xD;
Subjects with AEs considered related to study drug and any SAE regardless of causality were followed until resolution of the event or the subject was lost to follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>ODFS 8 mg With and Without Water and Zofran ODT Without Water</title>
          <description>Single dose of ondansetron ODFS 8 mg film administered with and without water and Zofran 8 mg administered without water in randomized sequence.&#xD;
Clinical laboratory hematology and chemistry tests were performed at screening (pre-study) and at the study follow-up visit (post-study). Thus, abnormal laboratory analytes reported as adverse events could not be attributed to any of the 3 study treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increase</sub_title>
                <description>ALT increased</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>AST increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood count increased</sub_title>
                <description>WBC count increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>Par Pharmaceutical</organization>
      <phone>800-828-9393</phone>
      <email>DrugInfo@strativapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

